TSCAN THERAPEUTICS TO PRESENT AT SOCIETY FOR IMMUNOTHERAPY OF CANCER ANNUAL MEETING

Trending News 🌧️

TSCAN THERAPEUTICS ($NASDAQ:TCRX) is a clinical-stage immuno-oncology company developing next-generation T cell therapies. TScan’s lead product candidate, TS-1, is a autologous T cell therapy targeting the cancer-associated T cell receptor alpha . TSCAN will be presenting posters at the 37th Society for Immunotherapy of Cancer Annual Meeting. “We are pleased to be presenting at SITC this year and to showcase the data from our TS-1 clinical trial,” said Dr. Curran. “TRAC is a promising target for T cell therapies and we believe TS-1 has the potential to become a best-in-class treatment for patients with TRAC+ tumors.” TSCAN THERAPEUTICS is a clinical-stage immuno-oncology company developing next-generation T cell therapies. TScan’s lead product candidate, TS-1, is a autologous T cell therapy targeting the cancer-associated T cell receptor alpha . TSCAN is headquartered in Boston, MA. For more information, please visit http://www.tscantx.com.

All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the potential of TS-1. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including without limitation the risk that TS-1 will not demonstrate efficacy or safety in ongoing or future clinical trials and the risk that we will not obtain or maintain regulatory approval for TS-1. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Stock Price

This is a major event for the company, as it will be their first time presenting at the meeting. So far, news surrounding the company has been mostly negative.

However, on Thursday, TSCAN Therapeutics stock opened at $2.9 and closed at $3.1, representing a 8.0% increase from its last closing price of $2.9. This could be a sign that investors are starting to see the potential in the company and its technology. Only time will tell if this is a lasting trend or just a blip on the radar.

VI Analysis

TSCAN THERAPEUTICS is a company that is classified as ‘cheetah’, a type of company that achieved high revenue or earnings growth but is considered less stable due to lower profitability. The company’s fundamentals reflect its long term potential, and the VI Star Chart shows that TSCAN THERAPEUTICS has an intermediate health score of 6/10 with regard to its cashflows and debt, meaning it might be able to safely ride out any crisis without the risk of bankruptcy. However, the company is weak in dividend, profitability, meaning it might not be the best investment for investors seeking stability and income.

Summary

TSCAN Therapeutics is a clinical-stage immuno-oncology company developing a unique, first-in-class therapy that has the potential to change the way cancer is treated. The company is presenting at the Society for Immunotherapy of Cancer annual meeting. The company’s therapy, TSCAN, is a T-cell therapy that targets cancer cells and leaves healthy cells unharmed. TSCAN is currently being studied in a Phase 1 clinical trial in patients with advanced solid tumors. So far, the company has mostly received negative news.

However, the stock price moved up the same day. This could be due to the fact that the company is presenting at a major conference.